December 19, 2023
Sanofi launched a new 200 mg syringe version of its IL-4/IL-13 inhibitor Dupixent (dupilumab) in Japan on December 18, offering a new treatment option for children with atopic dermatitis. While Dupixent has been available in 300 mg syringe and pen...read more